1. Scrip
  2. >>Leadership
  3. >>Executives On The Move

Appointments: Changes at SOTIO, Helsinn, Sobi, AMRI, Blade and Vertex

 
• By Sten Stovall

The latest biopharma industry appointments include a new chairman at Bone Therapeutics, chief executives at SOTIO and Helsinn Therapeutics, new CFOs at Sobi, AMRI and at Blade Therapeutics, and a new CMO at Vertex Pharmaceuticals.

Belgium-based Bone Therapeutics SA appointed Jean Stéphenne Chairman of the board of directors with immediate effect, replacing Steve Swinson who had informed the board of his intention to step down. Stéphenne's experience in life sciences include senior leadership roles at many biotechnology and pharmaceutical companies, most recently as chairman of TiGenix NV where, together with that rare disease company's board oversaw the clinical development and market approval of its most advanced allogeneic cell therapy product for the treatment of complex perianal fistulas in Crohn’s disease, resulting in Takeda Pharmaceutical Co. Ltd.’s announced intention to acquire the company. Also see "Takeda Gets Serious About Cell Therapy With TiGenix Buy" - Scrip, 5 January, 2018. Stéphenne was also previously a member of the corporate executive team of GlaxoSmithKline PLC and chief executive of GlaxoSmithKline Biologicals SA (now GSK Vaccines).

Sotio AS appointed Radek Špíšek as CEO effective March 1, replacing Ladislav Bartoníček, who has been CEO since early 2014 and will stay active within Sotio’s top management, replacing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Executives On The Move

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

Executives On The Move: Capricor Therapeutics Acquires Chief Medical Officer From Pfizer, Galapagos And Cellarity Get A New CEO, And More

Recent moves in the industry include new C-suite hires at Janux Therapeutics, BlueSphere Bio and Hansa Biopharma, plus Syndax Pharmaceuticals gets new chief medical officer from Bristol Myers Squibb.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

More from Leadership

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off

 
• By Anju Ghangurde

McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.